Ema Pleško

Ema Pleško

Auto-generated profile, based on publicly available information

Ema Pleško


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2026 in Cytotherapy
Verified
Journal Article
Open access
MBMatic Bartol
Matic Bartol
TFTina Fink
Tina Fink
TTTina Tragin
Tina Tragin
EPEma Pleško
Ema Pleško
RJRoman Jerala
Roman Jerala
MJMojca Jež
Mojca Jež
Efficient ex vivo activation is a critical determinant of T-cell expansion, engineering efficiency and functional programming in adoptive cell therapy manufacturing. Current activation platforms predominantly rely on nanoscale or magnetic particles that may undergo phagocytic uptake, require complex removal procedures and contribute to variability in monocyte-containing cultures. Here, we describe Atract T-Cell Activation Kit, a large-particle (40 μm) T-cell activation system designed to provide robust stimulation while simplifying downstream handling. Atract particles were not internalized by phagocytic cells in peripheral blood mononuclear cell up to 24 h, whereas 4.5 μm Dynabeads were internalized from 2 h onward. After size-based filtration, no residual particle was detected in 8 of 10 runs and never more than one, corresponding to 99.99997% removal. Benchmarked against TransAct, the activation reagent most widely used in clinical chimeric antigen receptor (CAR)-T manufacturing, Atract induced comparable activation, proliferation, viability and lentiviral transduction efficiencies while enriching for CD8⁺ T cells and preserving less differentiated memory-associated subsets. In CAR-T manufacturing workflows, Atract-activated cells showed higher cytotoxic activity against CD19⁺ targets than TransAct-activated cells, with lower secretion of selected pro-inflammatory cytokines and sustained granzyme B production following antigen engagement. Activation and expansion scaled across multiple G-Rex culture formats, supporting compatibility with translational manufacturing. Collectively, these findings indicate that activation particle architecture influences T-cell phenotype, functional programming and manufacturability. Atract represents a scalable activation platform that combines efficient T-cell stimulation with quantifiable clearance from the final product, resistance to phagocytic uptake and distinct CAR-T functional properties relevant to engineered cell therapy production.